| Acute Application of Pegvisomant and Octreotide in Acromegaly (NCT00595140) | Ludwig-Maximilians - University of Munich | 2008-01-01 |
| Inter-Assay Growth Hormone and IGF-I Variability (NCT00638287) | Cedars-Sinai Medical Center | 2007-11-01 |
| Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients (NCT00635765) | Ambrilia Biopharma, Inc. | 2007-10-01 |
| Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery (NCT00500227) | Ipsen | 2007-09-01 |
| Physiopathology of Sodium Retention in Acromegaly (NCT00531908) | Assistance Publique - Hôpitaux de Paris | 2007-09-01 |
| Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan (NCT00658879) | Pfizer | 2007-08-07 |
| Ultrasound Guided Octreotide LAR Injection in Acromegaly (NCT00552071) | Cedars-Sinai Medical Center | 2007-07-01 |
| Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States (NCT00461240) | Barts & The London NHS Trust | 2007-06-01 |
| Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel (NCT00447499) | Ipsen | 2007-04-01 |
| Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA (NCT00461188) | Barts & The London NHS Trust | 2007-03-01 |
| Open Label Study of Octreotide Implant in Patients With Acromegaly (NCT00913055) | Endo USA Inc., a Keenova Therapeutics Company | 2007-02-01 |
| Effects of Sandostatin LAR® in Acromegaly (NCT01424241) | Columbia University | 2006-10-01 |
| Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients (NCT00383708) | Ipsen | 2006-10-01 |
| Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients (NCT01278342) | Novartis Pharmaceuticals | 2006-09-01 |
| Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease (NCT00446082) | Novartis Pharmaceuticals | 2006-06-01 |
| Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant (NCT00552851) | University of Wuerzburg | 2006-06-01 |
| Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly (NCT00921609) | Cedars-Sinai Medical Center | 2006-06-01 |
| Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly (NCT00376064) | Novartis Pharmaceuticals | 2006-03-01 |
| Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly (NCT00372697) | Novartis Pharmaceuticals | 2005-12-01 |
| Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients (NCT01014793) | Federal University of São Paulo | 2005-05-01 |
| Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly (NCT00444873) | Ipsen | 2005-01-01 |
| Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone (NCT01029275) | University Hospital, Rouen | 2005-01-01 |
| Canadian Pegvisomant Compassionate Study In Acromegalic Patients (NCT00151437) | Pfizer | 2004-11-01 |
| An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly (NCT00171730) | Novartis Pharmaceuticals | 2004-08-24 |
| Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency (NCT00182091) | Massachusetts General Hospital | 2004-08-01 |
| Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR (NCT00216398) | Ipsen | 2004-06-01 |
| Long Term Study With B2036-PEG (NCT00143416) | Pfizer | 2004-04-01 |
| Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients (NCT00088582) | Novartis Pharmaceuticals | 2004-03-01 |
| Somatuline Autogel: Acromegaly Self/Partner Injection Study (NCT00149188) | Ipsen | 2004-02-01 |
| Non Interventional Study For Patients Treated With Somavert® (NCT00858143) | Pfizer | 2004-01-01 |
| Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas (NCT00993356) | Shanghai Jiao Tong University School of Medicine | 2004-01-01 |
| Pegvisomant And Sandostatin LAR Combination Study (NCT00068029) | Pfizer | 2003-10-01 |
| A Prospective Study of Outcome After Therapy for Acromegaly (NCT01809808) | Columbia University | 2003-09-01 |
| A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide (NCT00234520) | Ipsen | 2003-05-01 |
| A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly (NCT00068042) | Pfizer | 2003-04-01 |
| Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas (NCT00242541) | Novartis Pharmaceuticals | 2003-03-01 |
| Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly (NCT00627796) | Federico II University | 2003-01-01 |
| Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients (NCT00128232) | Novartis | 2002-12-01 |
| Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly (NCT00225979) | Novartis Pharmaceuticals | 2002-11-01 |
| Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction (NCT00145405) | Odense University Hospital | 2002-09-01 |
| Octreotide Efficacy and Safety in First-line Acromegalic Patients (NCT00171886) | Novartis Pharmaceuticals | 2002-07-01 |
| Fractionated Stereotactic Radiotherapy in Patients With Acromegaly (NCT00934271) | Rigshospitalet, Denmark | 2002-01-01 |
| Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly (NCT00499993) | Ipsen | 2001-01-01 |
| Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients (NCT00210457) | Ipsen | 2000-09-01 |
| Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly (NCT00234572) | Ipsen | 2000-05-01 |
| Preoperative Octreotide Treatment of Acromegaly (NCT00521300) | St. Olavs Hospital | 1999-09-01 |
| Measurement of Outcome of Surgical Treatment in Patients With Acromegaly (NCT00005100) | National Center for Research Resources (NCRR) | 1999-09-01 |
| Sandostatin LAR Depot vs. Surgery for Treating Acromegaly (NCT00001860) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1999-08-01 |
| Cardiovascular Outcome After Surgery or Somatostatin Analogues (NCT00615004) | Federico II University | 1997-01-01 |
| Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly (NCT00703079) | Federico II University | 1997-01-01 |
| Prediction of Tumor Shrinkage in Acromegaly (NCT00616408) | Federico II University | 1997-01-01 |
| Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly (NCT00004332) | National Center for Research Resources (NCRR) | 1993-05-01 |
| The Treatment and Natural History of Acromegaly (NCT00001981) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1991-10-02 |
| An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly (NCT01995734) | Novartis Pharmaceuticals | |
| Lanreotide Levels in Acromegaly (NCT00916916) | Cedars-Sinai Medical Center | |